These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29611342)

  • 1. The economic impacts of using adalimumab (Humira
    Schofield D; Shrestha R; Cunich M
    Int J Rheum Dis; 2018 May; 21(5):1106-1113. PubMed ID: 29611342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The costs of diabetes among Australians aged 45-64 years from 2015 to 2030: projections of lost productive life years (PLYs), lost personal income, lost taxation revenue, extra welfare payments and lost gross domestic product from Health&WealthMOD2030.
    Schofield D; Shrestha RN; Cunich MM; Passey ME; Veerman L; Tanton R; Kelly SJ
    BMJ Open; 2017 Jan; 7(1):e013158. PubMed ID: 28069621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
    Prince DS; McGuigan LE; McGirr EE
    Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The personal and national costs of early retirement because of spinal disorders: impacts on income, taxes, and government support payments.
    Schofield DJ; Shrestha RN; Percival R; Passey ME; Callander EJ; Kelly SJ
    Spine J; 2012 Dec; 12(12):1111-8. PubMed ID: 23092718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The personal and national costs of CVD: impacts on income, taxes, government support payments and GDP due to lost labour force participation.
    Schofield D; Shrestha R; Percival R; Passey M; Callander E; Kelly S
    Int J Cardiol; 2013 Jun; 166(1):68-71. PubMed ID: 22018513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    BioDrugs; 2020 Jun; 34(3):381-393. PubMed ID: 32078145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
    Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
    Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term economic impacts of arthritis through lost productive life years: results from an Australian microsimulation model.
    Schofield D; Cunich M; Shrestha RN; Tanton R; Veerman L; Kelly S; Passey ME
    BMC Public Health; 2018 May; 18(1):654. PubMed ID: 29793478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Informal caring for back pain: overlooked costs of back pain and projections to 2030.
    Schofield D; Zeppel MJB; Tanton R; Veerman J; Kelly S; Passey ME; Shrestha RN
    Pain; 2020 May; 161(5):1012-1018. PubMed ID: 31895264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The indirect costs of ischemic heart disease through lost productive life years for Australia from 2015 to 2030: results from a microsimulation model.
    Schofield D; Cunich M; Shrestha R; Passey M; Veerman L; Tanton R; Kelly S
    BMC Public Health; 2019 Jun; 19(1):802. PubMed ID: 31226965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depression prevention, labour force participation and income of older working aged Australians: A microsimulation economic analysis.
    Veerman JL; Shrestha RN; Mihalopoulos C; Passey ME; Kelly SJ; Tanton R; Callander EJ; Schofield DJ
    Aust N Z J Psychiatry; 2015 May; 49(5):430-6. PubMed ID: 25425743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic impact of diabetes through lost labour force participation on individuals and government: evidence from a microsimulation model.
    Schofield D; Cunich MM; Shrestha RN; Passey ME; Veerman L; Callander EJ; Kelly SJ; Tanton R
    BMC Public Health; 2014 Mar; 14():220. PubMed ID: 24592931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The personal and national costs of mental health conditions: impacts on income, taxes, government support payments due to lost labour force participation.
    Schofield DJ; Shrestha RN; Percival R; Passey ME; Callander EJ; Kelly SJ
    BMC Psychiatry; 2011 Apr; 11():72. PubMed ID: 21526993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
    Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.
    Lee SH; Park W; Won Lee S; Kim HA; Choe JY; Lee SH; Lee SS; Park SH; Park MC; Sheen DH; Lee HS; Lee YA; Lee Y; Kim TH
    Int J Rheum Dis; 2020 Aug; 23(9):1175-1183. PubMed ID: 32725789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.
    Kimel M; Revicki D; Rao S; Fryback D; Feeny D; Harnam N; Thompson C; Cifaldi M
    Clin Exp Rheumatol; 2011; 29(4):624-32. PubMed ID: 21813060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.